Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 175

1.

Dryinidae of the Afrotropical region (Hymenoptera, Chrysidoidea).

Olmi M, Copeland RS, VAN Noort S.

Zootaxa. 2019 Jul 10;4630(1):zootaxa.4630.1.1. doi: 10.11646/zootaxa.4630.1.1.

PMID:
31712497
3.

Novel targets for parkinsonism-depression comorbidity.

Tizabi Y, Getachew B, Csoka AB, Manaye KF, Copeland RL.

Prog Mol Biol Transl Sci. 2019;167:1-24. doi: 10.1016/bs.pmbts.2019.06.004. Epub 2019 Jul 8.

PMID:
31601399
4.

A Mass Spectrometric Assay of METTL3/METTL14 Methyltransferase Activity.

Buker SM, Gurard-Levin ZA, Wheeler BD, Scholle MD, Case AW, Hirsch JL, Ribich S, Copeland RA, Boriack-Sjodin PA.

SLAS Discov. 2019 Oct 4:2472555219878408. doi: 10.1177/2472555219878408. [Epub ahead of print]

PMID:
31585521
5.

Rebuttal to Response to the Article "Enzyme-Inhibitor Interactions and a Simple, Rapid Method for Determining Inhibition Modality".

Copeland RA.

SLAS Discov. 2020 Jan;25(1):8. doi: 10.1177/2472555219875106. Epub 2019 Sep 12. No abstract available.

PMID:
31513469
6.

Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss.

Fedoriw A, Rajapurkar SR, O'Brien S, Gerhart SV, Mitchell LH, Adams ND, Rioux N, Lingaraj T, Ribich SA, Pappalardi MB, Shah N, Laraio J, Liu Y, Butticello M, Carpenter CL, Creasy C, Korenchuk S, McCabe MT, McHugh CF, Nagarajan R, Wagner C, Zappacosta F, Annan R, Concha NO, Thomas RA, Hart TK, Smith JJ, Copeland RA, Moyer MP, Campbell J, Stickland K, Mills J, Jacques-O'Hagan S, Allain C, Johnston D, Raimondi A, Porter Scott M, Waters N, Swinger K, Boriack-Sjodin A, Riera T, Shapiro G, Chesworth R, Prinjha RK, Kruger RG, Barbash O, Mohammad HP.

Cancer Cell. 2019 Jul 8;36(1):100-114.e25. doi: 10.1016/j.ccell.2019.05.014. Epub 2019 Jun 27.

PMID:
31257072
7.

The Association of a Novel Identified VDR SNP With Prostate Cancer in African American Men.

Daremipouran MR, Beyene D, Apprey V, Naab TJ, Kassim OO, Copeland RL Jr, Kanaan YM.

Cancer Genomics Proteomics. 2019 Jul-Aug;16(4):245-255. doi: 10.21873/cgp.20129.

8.

Developing a theory-driven framework for a football intervention for men with severe, moderate or enduring mental health problems: a participatory realist synthesis.

Such E, Burton H, Copeland RJ, Davies R, Goyder E, Jeanes R, Kesterton S, Mackenzie K, Magee J.

J Ment Health. 2019 Mar 12:1-12. doi: 10.1080/09638237.2019.1581339. [Epub ahead of print]

PMID:
30862217
9.

Enzyme-Inhibitor Interactions and a Simple, Rapid Method for Determining Inhibition Modality.

Buker SM, Boriack-Sjodin PA, Copeland RA.

SLAS Discov. 2019 Jun;24(5):515-522. doi: 10.1177/2472555219829898. Epub 2019 Feb 27.

PMID:
30811960
10.
11.

A new edible cricket species from Africa of the genus Scapsipedus.

Tanga CM, Magara HJO, Ayieko MA, Copeland RS, Khamis FM, Mohamed SA, Ombura FLO, Niassy S, Subramanian S, Fiaboe KKM, Roos N, Ekesi S, Hugel S.

Zootaxa. 2018 Sep 28;4486(3):393-392. doi: 10.11646/zootaxa.4486.3.9.

PMID:
30313752
12.

Correlating blood-based DNA methylation markers and prostate cancer risk in African-American men.

Moses-Fynn E, Tang W, Beyene D, Apprey V, Copeland R, Kanaan Y, Kwabi-Addo B.

PLoS One. 2018 Sep 11;13(9):e0203322. doi: 10.1371/journal.pone.0203322. eCollection 2018.

13.

Kernel-Based Microfluidic Constriction Assay for Tumor Sample Identification.

Ren X, Ghassemi P, Kanaan YM, Naab T, Copeland RL, Dewitty RL, Kim I, Strobl JS, Agah M.

ACS Sens. 2018 Aug 24;3(8):1510-1521. doi: 10.1021/acssensors.8b00301. Epub 2018 Jul 18.

14.

Small molecule inhibitors and CRISPR/Cas9 mutagenesis demonstrate that SMYD2 and SMYD3 activity are dispensable for autonomous cancer cell proliferation.

Thomenius MJ, Totman J, Harvey D, Mitchell LH, Riera TV, Cosmopoulos K, Grassian AR, Klaus C, Foley M, Admirand EA, Jahic H, Majer C, Wigle T, Jacques SL, Gureasko J, Brach D, Lingaraj T, West K, Smith S, Rioux N, Waters NJ, Tang C, Raimondi A, Munchhof M, Mills JE, Ribich S, Porter Scott M, Kuntz KW, Janzen WP, Moyer M, Smith JJ, Chesworth R, Copeland RA, Boriack-Sjodin PA.

PLoS One. 2018 Jun 1;13(6):e0197372. doi: 10.1371/journal.pone.0197372. eCollection 2018.

15.

RNA-modifying proteins as anticancer drug targets.

Boriack-Sjodin PA, Ribich S, Copeland RA.

Nat Rev Drug Discov. 2018 Jun;17(6):435-453. doi: 10.1038/nrd.2018.71. Epub 2018 May 18. Review.

PMID:
29773918
16.

Identification of a peptide inhibitor for the histone methyltransferase WHSC1.

Morrison MJ, Boriack-Sjodin PA, Swinger KK, Wigle TJ, Sadalge D, Kuntz KW, Scott MP, Janzen WP, Chesworth R, Duncan KW, Harvey DM, Lampe JW, Mitchell LH, Copeland RA.

PLoS One. 2018 May 9;13(5):e0197082. doi: 10.1371/journal.pone.0197082. eCollection 2018.

17.

Four-horned wasps, description of some remarkable Dirhinus (Hymenoptera, Chalcididae) from Kenya, with a discussion of their taxonomic placement.

Delvare G, Copeland RS.

Zootaxa. 2018 Jan 18;4374(3):301-349. doi: 10.11646/zootaxa.4374.3.1.

PMID:
29689804
18.

Protein methyltransferase inhibitors as precision cancer therapeutics: a decade of discovery.

Copeland RA.

Philos Trans R Soc Lond B Biol Sci. 2018 Jun 5;373(1748). pii: 20170080. doi: 10.1098/rstb.2017.0080. Review.

19.

Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study.

Italiano A, Soria JC, Toulmonde M, Michot JM, Lucchesi C, Varga A, Coindre JM, Blakemore SJ, Clawson A, Suttle B, McDonald AA, Woodruff M, Ribich S, Hedrick E, Keilhack H, Thomson B, Owa T, Copeland RA, Ho PTC, Ribrag V.

Lancet Oncol. 2018 May;19(5):649-659. doi: 10.1016/S1470-2045(18)30145-1. Epub 2018 Apr 9.

PMID:
29650362
20.

An integrated motivational interviewing and cognitive-behavioural intervention promoting physical activity maintenance for adults with chronic health conditions: A feasibility study.

Scott SE, Breckon JD, Copeland RJ.

Chronic Illn. 2019 Dec;15(4):276-292. doi: 10.1177/1742395318769370. Epub 2018 Apr 11. No abstract available.

PMID:
29642707
21.

Active for Health Rotherham: be active to stay healthy.

Atchinson R, Frith G, Roden A, Copeland RJ, Reece LJ.

Br J Sports Med. 2019 Aug;53(16):1036-1037. doi: 10.1136/bjsports-2017-098676. Epub 2018 Jan 9. No abstract available.

PMID:
29317398
22.

Editorial: Obesity Stigma in Healthcare: Impacts on Policy, Practice, and Patients.

Flint SW, Oliver EJ, Copeland RJ.

Front Psychol. 2017 Dec 11;8:2149. doi: 10.3389/fpsyg.2017.02149. eCollection 2017. No abstract available.

23.

Identification of a CARM1 Inhibitor with Potent In Vitro and In Vivo Activity in Preclinical Models of Multiple Myeloma.

Drew AE, Moradei O, Jacques SL, Rioux N, Boriack-Sjodin AP, Allain C, Scott MP, Jin L, Raimondi A, Handler JL, Ott HM, Kruger RG, McCabe MT, Sneeringer C, Riera T, Shapiro G, Waters NJ, Mitchell LH, Duncan KW, Moyer MP, Copeland RA, Smith J, Chesworth R, Ribich SA.

Sci Rep. 2017 Dec 21;7(1):17993. doi: 10.1038/s41598-017-18446-z.

24.

The Elements of Translational Chemical Biology.

Copeland RA, Boriack-Sjodin PA.

Cell Chem Biol. 2018 Feb 15;25(2):128-134. doi: 10.1016/j.chembiol.2017.11.003. Epub 2017 Dec 7. Review.

25.

DHPLC Elution Patterns of VDR PCR Products Can Predict Prostate Cancer Susceptibility in African American Men.

Copeland RL, Beyene D, Apprey V, Daremipouran MR, Naab TJ, Kassim OO, Kanaan YM.

Cancer Genomics Proteomics. 2017 Nov-Dec;14(6):461-467. Review.

26.
27.

Drug Discovery and Chemical Biology of Cancer Epigenetics.

Ribich S, Harvey D, Copeland RA.

Cell Chem Biol. 2017 Sep 21;24(9):1120-1147. doi: 10.1016/j.chembiol.2017.08.020. Review.

28.

EZH2 Inhibition by Tazemetostat Results in Altered Dependency on B-cell Activation Signaling in DLBCL.

Brach D, Johnston-Blackwell D, Drew A, Lingaraj T, Motwani V, Warholic NM, Feldman I, Plescia C, Smith JJ, Copeland RA, Keilhack H, Chan-Penebre E, Knutson SK, Ribich SA, Raimondi A, Thomenius MJ.

Mol Cancer Ther. 2017 Nov;16(11):2586-2597. doi: 10.1158/1535-7163.MCT-16-0840. Epub 2017 Aug 23.

29.

Breast Cancer Prognosis for Young Patients.

Owrang M, Copeland RL Jr, Ricks-Santi LJ, Gaskins M, Beyene D, Dewitty RL Jr, Kanaan YM.

In Vivo. 2017 Jul-Aug;31(4):661-668.

30.

Mechanisms of Pinometostat (EPZ-5676) Treatment-Emergent Resistance in MLL-Rearranged Leukemia.

Campbell CT, Haladyna JN, Drubin DA, Thomson TM, Maria MJ, Yamauchi T, Waters NJ, Olhava EJ, Pollock RM, Smith JJ, Copeland RA, Blakemore SJ, Bernt KM, Daigle SR.

Mol Cancer Ther. 2017 Aug;16(8):1669-1679. doi: 10.1158/1535-7163.MCT-16-0693. Epub 2017 Apr 20.

31.

Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2: In Vitro and In Vivo Preclinical Models.

Chan-Penebre E, Armstrong K, Drew A, Grassian AR, Feldman I, Knutson SK, Kuplast-Barr K, Roche M, Campbell J, Ho P, Copeland RA, Chesworth R, Smith JJ, Keilhack H, Ribich SA.

Mol Cancer Ther. 2017 May;16(5):850-860. doi: 10.1158/1535-7163.MCT-16-0678. Epub 2017 Mar 14.

32.

Correction: Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma.

Kawano S, Grassian AR, Tsuda M, Knutson SK, Warholic NM, Kuznetsov G, Xu S, Xiao Y, Pollock RM, Smith JJ, Kuntz KW, Ribich S, Minoshima Y, Matsui J, Copeland RA, Tanaka S, Keilhack H.

PLoS One. 2017 Jan 13;12(1):e0170539. doi: 10.1371/journal.pone.0170539. eCollection 2017.

34.

Drug-target interaction kinetics: underutilized in drug optimization?

Copeland RA.

Future Med Chem. 2016 Dec;8(18):2173-2175. Epub 2016 Nov 15. No abstract available.

PMID:
27845591
35.

'I just don't want to get bullied anymore, then I can lead a normal life'; Insights into life as an obese adolescent and their views on obesity treatment.

Reece LJ, Bissell P, Copeland RJ.

Health Expect. 2016 Aug;19(4):897-907. doi: 10.1111/hex.12385. Epub 2015 Jul 17.

36.

Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma.

Kawano S, Grassian AR, Tsuda M, Knutson SK, Warholic NM, Kuznetsov G, Xu S, Xiao Y, Pollock RM, Smith JS, Kuntz KK, Ribich S, Minoshima Y, Matsui J, Copeland RA, Tanaka S, Keilhack H.

PLoS One. 2016 Jul 8;11(7):e0158888. doi: 10.1371/journal.pone.0158888. eCollection 2016. Erratum in: PLoS One. 2017 Jan 13;12 (1):e0170539.

37.

Characterization of Inhibitor Binding Through Multiple Inhibitor Analysis: A Novel Local Fitting Method.

Riera TV, Wigle TJ, Copeland RA.

Methods Mol Biol. 2016;1439:33-45. doi: 10.1007/978-1-4939-3673-1_2.

PMID:
27316986
38.
39.

The weight-loss experience: a qualitative exploration.

Rogerson D, Soltani H, Copeland R.

BMC Public Health. 2016 May 4;16:371. doi: 10.1186/s12889-016-3045-6.

40.

Structure and Property Guided Design in the Identification of PRMT5 Tool Compound EPZ015666.

Duncan KW, Rioux N, Boriack-Sjodin PA, Munchhof MJ, Reiter LA, Majer CR, Jin L, Johnston LD, Chan-Penebre E, Kuplast KG, Porter Scott M, Pollock RM, Waters NJ, Smith JJ, Moyer MP, Copeland RA, Chesworth R.

ACS Med Chem Lett. 2015 Dec 2;7(2):162-6. doi: 10.1021/acsmedchemlett.5b00380. eCollection 2016 Feb 11.

41.

Novel Oxindole Sulfonamides and Sulfamides: EPZ031686, the First Orally Bioavailable Small Molecule SMYD3 Inhibitor.

Mitchell LH, Boriack-Sjodin PA, Smith S, Thomenius M, Rioux N, Munchhof M, Mills JE, Klaus C, Totman J, Riera TV, Raimondi A, Jacques SL, West K, Foley M, Waters NJ, Kuntz KW, Wigle TJ, Scott MP, Copeland RA, Smith JJ, Chesworth R.

ACS Med Chem Lett. 2015 Aug 27;7(2):134-8. doi: 10.1021/acsmedchemlett.5b00272. eCollection 2016 Feb 11.

42.

Epigenetic Medicinal Chemistry.

Copeland RA.

ACS Med Chem Lett. 2015 Dec 10;7(2):124-7. doi: 10.1021/acsmedchemlett.5b00462. eCollection 2016 Feb 11.

43.

Embedding Physical Activity in the Heart of the NHS: The Need for a Whole-System Approach.

Speake H, Copeland RJ, Till SH, Breckon JD, Haake S, Hart O.

Sports Med. 2016 Jul;46(7):939-46. doi: 10.1007/s40279-016-0488-y.

44.

Sheffield Hallam Staff Wellness service: Four-year follow-up of the impact on health indicators.

Flint SW, Scaife R, Kesterton S, Humphreys L, Copeland R, Crank H, Breckon J, Maynard I, Carter A.

Perspect Public Health. 2016 Sep;136(5):295-301. doi: 10.1177/1757913916630009. Epub 2016 Feb 29.

PMID:
26929246
45.

Recruiting to a large-scale physical activity randomised controlled trial - experiences with the gift of hindsight.

Copeland RJ, Horspool K, Humphreys L, Scott E; Booster trial team.

Trials. 2016 Feb 24;17(1):104. doi: 10.1186/s13063-016-1229-0.

46.

CARM1 Preferentially Methylates H3R17 over H3R26 through a Random Kinetic Mechanism.

Jacques SL, Aquino KP, Gureasko J, Boriack-Sjodin PA, Porter Scott M, Copeland RA, Riera TV.

Biochemistry. 2016 Mar 22;55(11):1635-44. doi: 10.1021/acs.biochem.5b01071. Epub 2016 Feb 5.

PMID:
26848779
47.

PRC2 and SWI/SNF Chromatin Remodeling Complexes in Health and Disease.

Kadoch C, Copeland RA, Keilhack H.

Biochemistry. 2016 Mar 22;55(11):1600-14. doi: 10.1021/acs.biochem.5b01191. Epub 2016 Feb 17. Review.

PMID:
26836503
48.

Characterization of the Enzymatic Activity of SETDB1 and Its 1:1 Complex with ATF7IP.

Basavapathruni A, Gureasko J, Porter Scott M, Hermans W, Godbole A, Leland PA, Boriack-Sjodin PA, Wigle TJ, Copeland RA, Riera TV.

Biochemistry. 2016 Mar 22;55(11):1645-51. doi: 10.1021/acs.biochem.5b01202. Epub 2016 Feb 11.

PMID:
26813693
49.

The Importance of Being Me: Magic Methyls, Methyltransferase Inhibitors, and the Discovery of Tazemetostat.

Kuntz KW, Campbell JE, Keilhack H, Pollock RM, Knutson SK, Porter-Scott M, Richon VM, Sneeringer CJ, Wigle TJ, Allain CJ, Majer CR, Moyer MP, Copeland RA, Chesworth R.

J Med Chem. 2016 Feb 25;59(4):1556-64. doi: 10.1021/acs.jmedchem.5b01501. Epub 2016 Jan 27.

PMID:
26769278
50.

The Biochemistry of Chromatin Remodeling.

Copeland RA.

Biochemistry. 2016 Mar 22;55(11):1555-6. doi: 10.1021/acs.biochem.6b00014. Epub 2016 Jan 22. No abstract available.

PMID:
26745206

Supplemental Content

Loading ...
Support Center